MILAN, Sept. 15, 2025 /PRNewswire/ — Amplifon, a global leader in hearing solutions and services, is launching its climate strategy validated by the Science Based Targets Initiative (SBTi) to reduce greenhouse gas emissions and contribute to achieving the goals of the 2015 Paris Agreement to counteract climate change.

The strategy, “Listening to our Planet,” specifically calls for a 42% reduction in the company’s direct greenhouse gas emissions (Scope 1 and 2) by 2030 compared to 2023. Over the same period, the company has committed to reducing indirect Scope 3 emissions by 25%, deriving from purchased goods and services, capital goods, fuel and energy related activities, upstream transportation and distribution, employee commuting, upstream leased assets, use of sold products and franchises. The plan also stipulates that, by 2030, 44.36% of its suppliers in terms of emissions related to purchased goods and services will have greenhouse gas emission reduction targets based on climate science.

“The launch of a scientifically validated climate strategy,” comments Amplifon CEO Enrico Vita, “represents a further step forward in the process of fully integrating ESG factors into our business. Making concrete commitments to reduce our direct and indirect emissions in the medium term is in line with the sustainability plan we launched last year with 20 concrete and measurable targets for 2026, 2028, and 2030 in the areas of products and services, ethics and environmental responsibility, people, and communities. We want to continue to grow in an increasingly responsible and sustainable manner.”

The Science Based Targets Initiative, a non-profit organization launched in 2015 by a coalition of international actors such as CDP, UN Global Compact, World Resources Institute, WWF, and We Mean Business Coalition, supports companies in setting greenhouse gas emission reduction targets consistent with the latest scientific evidence on climate change.

Amplifon’s Corporate Website 

Amplifon’s Sustainability Plan

New Climate Strategy

Amplifon

Amplifon, hearing care global leader, empowers people to rediscover all the emotions of sound. Amplifon’s over 20,000 people worldwide strive every day to understand the unique needs of every customer, delivering exclusive, innovative and highly personalized products and services, to ensure everyone the very best solution and outstanding experience. The Group, with annual revenues of over 2.4 billion euros, operates through a network of over 10,000 points of sale in 26 Countries and 5 continents.

Together we’re unlocking the true potential of clinical trial lab data, bringing faster insights, smarter decisions, and better outcomes.

JOHNSON CITY, Tenn. and HOUSTON, Sept. 15, 2025 /PRNewswire/ — LabConnect, a leading global provider of central laboratory services today announced plans to form a strategic collaboration with OmniScience, the AI company behind Vivo, the first agentic AI control tower for clinical trials. Together, they will deliver the industry’s first AI-driven solution enabling sponsors to gain intelligent, real-time insights from clinical trial lab data.

LabConnect and OmniScience logos

Faster Decisions and Smarter Oversight with LabConnect + Vivo 
Clinical trial lab data is often siloed, complex, and delayed. This causes slow decision-making and introduces risk. By combining LabConnect’s expertise in central lab testing and data management with OmniScience’s Vivo platform, trial sponsors can now unify fragmented lab datasets, automate oversight, and surface risk signals that accelerate trial timelines and improve outcomes.

About Vivo: Real-Time Intelligence for Clinical Trials, Purpose-Built for Lab Data
Vivo is an AI-native clinical trial intelligence platform that transforms how teams interact with data across the clinical development lifecycle. Designed to unify disparate sources and deliver real-time insights, Vivo functions as a control tower equipping clinical, operational, safety, and data science teams with the clarity to act faster and more confidently. Vivo-Lab, a specialized implementation of Vivo, brings this same intelligence to laboratory data. Vivo-Lab streamlines lab workflows by surfacing critical trends, anomalies, and site-level discrepancies as they happen, helping teams move from reactive to proactive oversight in one of the most complex and variable data streams in clinical research.

Transforming Lab Data into Real-Time Action
“Our mission at OmniScience is to help trial teams see and act faster,” said Angela Holmes, CEO and Co-Founder of OmniScience. “Partnering with LabConnect extends that vision by transforming lab data into real time actionable intelligence that sponsors can trust.”

Wes Wheeler, CEO of LabConnect, added: “At LabConnect, we’re committed to helping sponsors unlock the full potential of their lab data. By integrating OmniScience’s transformative AI, we are shifting lab results from static reports into dynamic, actionable intelligence. Together, we’re giving clinical operations teams the speed, agility, and precision they need to make smarter decisions, improve trial efficiency, and bring therapies to patients faster.”

The partnership underscores both organizations’ commitment to innovation in clinical development, bringing together LabConnect’s technology-driven laboratory operations and OmniScience’s AI-native approach to trial intelligence.

About LabConnect
LabConnect, LLC is the leading provider of Central Laboratory Services, FSP and Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases.

LabConnect’s unique combination of state-of-the-art technology, world-class laboratories, easy access to major and emerging markets, and extensive specialized testing expertise means that drug development companies can rely on one provider for all their central laboratory service needs.

Learn more at www.labconnect.com and follow on LinkedIn.

About OmniScience
OmniScience is a leading AI company transforming clinical development with Vivo, the first agentic AI control tower purpose-built for clinical trials. Built by a team of PhD-trained clinical data scientists, Vivo unifies fragmented trial data, applies intelligent automation, and delivers real-time, explainable insights that help sponsors reduce costs, shorten timelines, and increase trial success rates. Award winning and recognized by programs including Johnson & Johnson’s JLABS, NVIDIA Inception, and Google Cloud for AI, OmniScience is pioneering a new era of clinical trial intelligence to accelerate the delivery of life-changing treatments to patients.

VANCOUVER, BC, Sept. 15, 2025 /PRNewswire/ — WAT Medical Enterprise Ltd. is proud to announce that its innovative anti-nausea wristband, EmeTerm, has made significant progress in alleviating nausea and vomiting among patients suffering from chronic gastric disorders. A clinical study currently underway at The Ohio State University Wexner Medical Center is evaluating the device’s impact on individuals with moderate to severe chronic nausea, a condition that affects millions worldwide.

A Growing Unmet Medical Need
Chronic nausea and vomiting remain challenging to treat. According to the American College of Gastroenterology (ACG), up to 12% of the U.S. population may suffer from functional dyspepsia and related chronic gastric disorders, with nausea being one of the most debilitating symptoms (ACG Clinical Guideline, 2022). Standard antiemetic medications often carry side effects such as fatigue, dizziness, and constipation, limiting long-term use.

Globally, the antiemetic drug market was valued at USD 4.8 billion in 2022 and is projected to grow at a CAGR of 6.2% through 2030 (Grand View Research, 2023). The demand for safe, non-invasive, drug-free alternatives is steadily rising.

How EmeTerm Works
EmeTerm employs transcutaneous electrical acustimulation (TEAS) technology. The device delivers gentle electrical pulses to the median nerve on the wrist, modulating neural signals between the gut and the brain. This mechanism helps reduce nausea and prevent vomiting—without the side effects typically associated with pharmacological treatments.

Clinical evidence supports EmeTerm efficacy of reduce nausea and prevent vomiting. A multicenter randomized controlled trial demonstrated that EmeTerm significantly reduced the incidence of postoperative nausea and vomiting (PONV) in patients undergoing hysteroscopic surgery (Wang, 2022).

Unlike medications that must be taken regularly, EmeTerm can be worn on-demand, making it a practical tool for individuals managing unpredictable or chronic episodes of nausea. EmeTerm is already FDA-cleared as an over-the-counter device for nausea relief, including motion sickness and pregnancy-related nausea.

Promising Strides at Ohio State University

Ohio State University hopes to conduct research on using modern medical technologies to control chronic gastrointestinal diseases. Since 2023, The Ohio State University Wexner Medical Center has been conducting a clinical study to evaluate the potential of EmeTerm as a supportive therapy for chronic gastrointestinal disorders. 

This trial marks a critical step in evaluating its potential as a therapeutic adjunct for chronic gastrointestinal conditions. Final study results are anticipated in the coming months. Recent results show that nearly 50% of patients with moderate to severe nausea experienced meaningful relief, while approximately 30% of participants suffering from vomiting also reported improvement.

The study, launched in 2023 and expected to conclude in 2026, is closely monitoring patients with conditions such as gastroparesis, chronic gastritis, and other gastrointestinal disorders. Researchers are tracking the device’s effectiveness across a wide spectrum of gastric diseases to confirm its benefits for a broad patient population.

–  A powerhouse partnership in family entertainment to reintroduce a timeless stop-motion classic to new audiences in Korea

Download image here

SEOUL, South Korea, Sept. 15, 2025 /PRNewswire/ — The Pinkfong Company, the global entertainment company behind Baby Shark, announced an exclusive distribution partnership with Mattel, Inc. (NASDAQ: MAT), a leading global toy and family entertainment company and owner of one of the most iconic brand portfolios in the world, to reintroduce the beloved stop-motion classic Pingu to audiences in Korea. The Pinkfong Company will exclusively distribute Pingu episodes from the 90s and 2000s in the domestic market, including the Pingu Classic Series, the Pingu at the Wedding Party special, and Pingu in the City. The episodes will premiere on September 19, with new episodes released weekly on leading pay-TV and digital platforms.

With original family IPs such as Baby Shark and Bebefinn, The Pinkfong Company has built a diverse portfolio that resonates with audiences of all ages. Mattel, renowned for iconic global brands including Barbie and Hot Wheels, continues to expand its storytelling across content and media. Through this partnership, the two companies are creating meaningful synergies — combining Mattel’s IP with The Pinkfong Company’s growing role as a trusted local partner in distributing internationally renowned properties.

Since its debut in the 1980s, Pingu has won the hearts of audiences in more than 150 countries with its whimsical stop-motion charm and universal humor. Featuring the mischievous young penguin and his signature “Noot Noot!,” the series blends family themes with timeless comedy, cementing its status as a beloved pop culture icon across generations.

“Pingu is one of the most iconic stop-motion properties of all time, and we are thrilled to bring this timeless classic back to Korean audiences through our partnership with Mattel,” said Gemma Joo, Chief Business Officer at The Pinkfong Company. “This marks an exciting new chapter in sharing Pingu‘s universal charm and playful spirit, reinforcing our dedication to family entertainment that transcends generations.”

“Mattel is excited to partner with The Pinkfong Company to reintroduce Pingu’s adventures to a new generation of fans in Korea,” said Alex Godfrey, Vice President, Global Content Distribution at Mattel. “We are committed to sharing our iconic brands with audiences worldwide and look forward to building upon Pingu’s impact and enduring global appeal.”

This partnership reflects The Pinkfong Company’s ongoing commitment to delivering high-quality family entertainment through its original IPs and key collaborations with leading global brands like Mattel. It also underscores the company’s mission to bring joyful content that connects audiences across generations and regions.

About The Pinkfong Company

The Pinkfong Company is a global entertainment company that delivers content and entertaining experiences around the world. Driven by award-winning brands and IPs, the company has created and distributed a range of content across genres and formats including original animated series, world live tours, interactive games, and more. Believing in the power of entertaining and engaging content, The Pinkfong Company is committed to connecting people around the world and bringing joy and inspiration to worldwide audiences of all ages. For more information, please visit the website or follow the company on LinkedIn.

About Mattel

Mattel is a leading global toy and family entertainment company and owner of one of the most iconic brand portfolios in the world. We engage consumers and fans through our franchise brands, including Barbie®, Hot Wheels®, Fisher-Price®, American Girl®, Thomas & Friends™, UNO®, Masters of the Universe®, Matchbox®, Monster High®, Polly Pocket®, and Barney®, as well as other popular properties that we own or license in partnership with global entertainment companies. Our offerings include toys, content, consumer products, digital and live experiences. Our products are sold in collaboration with the world’s leading retail and ecommerce companies. Since its founding in 1945, Mattel is proud to be a trusted partner in empowering generations to explore the wonder of childhood and reach their full potential. Visit us at mattel.com

Media Contact
Hailey Kim
Communications Manager
The Pinkfong Company
hailey@pinkfong.com

Kensie Sanchez Krompier
Mattel
Kensie.Krompier@mattel.com

RANCHO CUCAMONGA, Calif., Sept. 15, 2025 /PRNewswire/ — FEELINGIRL, a brand renowned for its technology-driven shapewear, once again took center stage with the FEELINGIRL Bra collection. Dedicated to enhancing women’s confidence, FEELINGIRL is committed to creating comfortable, close-fitting lingerie designed for women of all ages and life stages. With its latest FeelCare collection, the brand has been honored with the Silver Award in the Fashion Design category at the prestigious MUSE Design Awards.

The MUSE Design Awards, one of the most prestigious honors in the global design community, celebrates innovation and excellence across multiple disciplines. This year’s competition attracted nearly 10,000 entries from around the world, with evaluation criteria spanning creativity, functionality, social value, and breakthroughs in aesthetics.

The award-winning FeelCare collection represents the culmination of the brand’s long-standing commitment to fabric technology innovation for the FEELINGIRL Bra collection. Trusted by consumers, the FEELINGIRL Bra collection has earned recognition for comfort, functional materials, and technology-driven shaping. The brand invests in textile research and development, advancing support, breathability, and skin-friendliness. With years of expertise in everyday lingerie, FEELINGIRL has transferred these innovations to the demanding field of post-surgery recovery, creating a milestone collection that combines medical functionality with human-centered design.

The FEELINGIRL FeelCare post-surgery shapewear collection is a product line designed with women’s recovery needs as its primary focus. Developed with ergonomic structure, intelligent support systems, and advanced functional fabrics, the collection provides tailored solutions for the unique challenges women face during post-surgical recovery. Two core products anchor the collection: a post-surgery bra and shaping pants. Together, they target the chest and waist-abdominal regions to deliver reliable support and contouring, balancing practicality with comfort across various daily scenarios, from early recovery to commuting or at-home wear.

The post-surgery bra stands out for its thoughtful details and focus on both comfort and support. Its full-coverage, wire-free construction avoids padded cups while offering a stable structure, minimizing pressure and movement during sensitive recovery stages. Bust-enhancing panels subtly lift and shape, while the hem features the brand’s exclusive logo elastic band that prevents sagging and ensures secure contouring. Inside, a molding process creates space for a seamless, natural bust profile. Wide, adjustable shoulder straps reduce shoulder strain while enhancing back contours. For convenience, especially important during recovery, the bra incorporates a front-center three-row hook design, allowing easier dressing and a better fit for different body types.

Complementing the bra, the shaping pants emphasize waist and abdominal support with a high-waist, double-layer compression structure. This design stabilizes the waistline, flattens the stomach, and defines contours, while built-in lifting panels naturally enhance the hips to create a seamless, sculpted silhouette. Boning in the back waist prevents rolling and supports lumbar stability, while a front zipper-and-hook system ensures secure wear. A separate crotch zipper enhances practicality, recognizing the everyday needs of women in recovery.

Beyond individual product features, the FeelCare collection distinguishes itself through structural optimization rooted in multidimensional human body curve data. By applying zoned compression technology, the garments provide precise shaping and support for the waist, abdomen, and hips. A 360-degree four-way stretch wrap enhances comfort, while the front waist-abdomen incorporates a shaping mesh layer to create a three-layer contouring system. These innovations together form a collection that merges science-driven precision with user-focused comfort.

In a competitive global field, the FeelCare collection stood out for its ability to address women’s post-surgery recovery needs with products that respect both function and dignity. With the FeelCare collection, FEELINGIRL has demonstrated that shapewear can serve as more than a functional garment; it can become a meaningful part of recovery and confidence-building. The award signals a significant step for the brand on the global stage, reaffirming its commitment to advancing women’s health through thoughtful design and innovation.

For more details, please visit: https://feelingirl.com/ or search “FEELINGIRL” on Amazon.   

SEOUL, South Korea , Sept. 15, 2025 /PRNewswire/ — South Korean startup MAS9 has made a rapid entry into the U.S. Taekwondo market, onboarding more than 100 schools within a month of launching its paid SaaS platform. The company’s solution is the first business-to-business-to-consumer (B2B2C) digital management system designed specifically for martial arts schools in the United States.

The platform replaces manual administrative tasks—such as tuition collection, overdue payment reminders, and attendance tracking—with a fully automated system. Parents and students also benefit from real-time access to class schedules, training progress, and instructor feedback via MAS9’s dedicated mobile app and website.

Building on this momentum, MAS9 will introduce a one-click e-commerce feature in January 2026, giving school owners a new revenue opportunity. Without carrying inventory, owners will be able to launch online shops and sell uniforms, equipment, and merchandise directly to students and parents through the platform. The U.S. Taekwondo merchandise market is estimated at around $400 million, and MAS9’s upcoming feature is designed to help school operators capture this demand more effectively..

“MAS9 provides both operational efficiency and financial upside for school owners, which explains the strong adoption we’ve seen in such a short time,” said Dongho Ryoo, CEO of MAS9 USA. He added that the company has been able to accelerate adoption by rapidly incorporating feedback from U.S. school operators, leveraging more than two decades of local market experience.

Looking forward, MAS9 plans to integrate artificial intelligence into its system, with features such as student retention analytics, personalized training content, and financial forecasting tools.

Sang-Youb Lee, CEO of MAS9 said the company’s long-term ambition is to build a global Taekwondo business platform. “With 700,000 schools, 1.5 million instructors, and 80 million practitioners worldwide, Taekwondo represents a massive opportunity. Our early success in the U.S. validates our strategy and lays the groundwork for international expansion.”

Supply chain planning veteran brings technical expertise, experience scaling go-to-market functions to lead company through next phase of growth

WILMINGTON, Del., Sept. 15, 2025 /PRNewswire/ — Arkieva, a provider of industry-leading supply chain planning solutions, announces Anand Iyer as its new CEO. Iyer brings 30 years of experience to Arkieva, with a proven track record of leading organizations through transformational periods. His supply chain and technology background includes leadership roles at i2 Technologies, now Blue Yonder, and Serus Corporation, now e2Open.

“Arkieva has a strong foundation, and I’m confident that Anand is the right leader to take the company forward,” says Harpal Singh, Founder, Arkieva. “Throughout his career, he’s earned praise as an inspiring leader, with a record of helping clients with innovative strategies. As global supply chains continue to evolve, his expertise and vision are the right fit to drive this next phase of growth for Arkieva.”

Iyer joins Arkieva at a pivotal stage of the company’s history, following Banneker Partners’ strategic investment in the company earlier this year. The partnership aims to equip Arkieva for a new phase of growth, enabling the company to sustain its leading position and address evolving market demand.

“Arkieva has built a strong reputation for delivering measurable results for clients facing complex supply chain challenges,” says Iyer. “In this next phase, I look forward to expanding on that track record as our customers strive to build agile and resilient supply chains amid shifting trade rules and increasing global pressures.”

Arkieva was recently positioned as a Challenger in the 2025 Gartner Magic Quadrant^™ for Supply Chain Planning Solutions. The company’s modern SaaS suite, which offers unrivaled digital twin and autonomous control tower capabilities, is trusted by global manufacturers and distributors to manage over $110 billion in revenue planning.

“As Anand worked with the leadership team to develop the best path ahead for Arkieva, it became clear that he is not only a trusted advisor, but the right person to guide Arkieva into its next phase of growth as CEO,” says Chirag Shah, Operating Partner at Banneker Partners. “Anand’s deep expertise in supply chain strategy, planning and execution, combined with his experience driving operational excellence, make him the right leader to strengthen Arkieva’s position as a trusted partner.”

Iyer holds a doctorate in Systems and Industrial Engineering from the University of Arizona. Outside of the supply chain industry, he has served in upper management positions at Quantum Spatial, a geospatial analytics firm, and Riverside Insights, a specialist in research-backed educational and clinical assessments.

To access images, click here.

About Arkieva
For more than 30 years, Arkieva has helped global enterprises drive business transformation through improved supply chain processes. The company’s demand, inventory, supply and integrated business planning solutions increase growth and profits, and provide the agility and efficiency needed to respond to an ever-changing supply chain environment. Our approach combines strategic consultation, powerful software technologies and iterative implementation to deliver scalable solutions tailored to the complexities of each customer’s operations. Arkieva’s culture of innovation keeps customers like Linde, Messer and INEOS at the forefront of supply chain planning.

Arkieva is headquartered in Wilmington, Delaware USA with offices in Antwerp, Belgium and Mangalore, India. For more information, visit www.arkieva.com.

CONNECT WITH ARKIEVA

• Follow Arkieva on LinkedIn
• Follow Arkieva on X
• Like Arkieva on Facebook
• Subscribe to the Arkieva YouTube Channel
• Subscribe to the Arkieva Supply Chain Link Blog

Arkieva Media Contact:
Kristan Theile
Director of Marketing, Arkieva
513-376-0300
ktheile@arkieva.com